Alpha Cognition Inc. Announces NMPA Acceptance of ZUNVEYL NDA for Alzheimer's Treatment in China
Alpha Cognition Inc. announced that its partner, China Medical System Holdings Limited, has received acceptance for their New Drug Application (NDA) for ZUNVEYL® (Benzgalantamine) by the National Medical Products Administration of China. This treatment targets mild-to-moderate Alzheimer’s dementia and marks a significant step towards introducing it to the Asian market. Alpha Cognition will benefit from CMS’s expertise and receive financial gains upon ZUNVEYL’s approval for marketing in China and other Asian territories.
Alpha Cognition Inc., a biopharmaceutical company specializing in therapies for neurodegenerative disorders, announced that their partner, China Medical System Holdings Limited (CMS), has received acceptance for their New Drug Application (NDA) by the National Medical Products Administration of China (NMPA). This NDA pertains to ZUNVEYL® (Benzgalantamine), a treatment aimed at mild-to-moderate Alzheimer’s dementia. This milestone signifies a critical step toward potentially introducing this innovative therapy to the Asian market. Alpha Cognition is set to benefit from CMS’s regulatory and commercial expertise in China and will receive financial gains such as regulatory and sales milestones, and royalties upon ZUNVEYL’s approval for marketing in China and other Asian territories. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250729192664) on July 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
